Not a good buy right now for an impatient trader: no proprietary buy signals, weak near-term statistical drift, and heavy hedge-fund selling pressure.
Technicals are still broadly constructive (bullish MA stack), but momentum is fading (MACD contracting) and price sits below/near pivot—risk of a breakdown to support.
I would wait for either (1) a clear rebound/close back above ~21.63 pivot with improving momentum, or (2) a cleaner dip-and-hold near ~20.80/20.28 support before considering a fast entry.
Momentum: MACD histogram is positive (0.0164) but contracting, indicating bullish momentum is weakening.
RSI: RSI_6 ~44.1 (neutral-to-soft), not oversold—doesn’t signal a strong dip-buy setup yet.
Levels: Pivot 21.63 is the key line; below it the tape is weaker. Supports: 20.80 (S1) then 20.28 (S2). Resistances: 22.46 (R1) then 22.98 (R2).
Near-term pattern stats: Similar-pattern outlook implies slight negative bias (-0.15% next day, -0.45% next week, -1.61% next month), which is not supportive for an immediate buy.
Positive Catalysts
and recovers above pivot (~21.63), it could set up a quick mean-reversion move toward 22.46–22.
Insiders show no significant recent trading trend (neutral), avoiding an obvious insider-sell red flag.
Neutral/Negative Catalysts
Intellectia signals: AI Stock Picker = no signal; SwingMax = no recent signal (no high-conviction tactical entry from the provided system).
Hedge funds are selling aggressively (selling amount up ~1048.78% QoQ), which is a meaningful sentiment/flow headwind.
Momentum is weakening (MACD contracting) while price is down on the day (-2.90%) in a risk-off market (S&P 500 -1.09%).
No recent news/catalysts provided to justify an urgent entry; without a catalyst, drift lower toward support is plausible.
Financial Performance
Financial snapshot unavailable (data error: list index out of range), so latest quarter results and growth trends (latest quarter season) cannot be assessed from the provided data.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating/price target change data provided, so recent Street sentiment shifts and bull/bear case changes cannot be evaluated from the dataset.
Practical takeaway: absent confirmed positive revisions or raised targets, there’s no analyst-driven reason to chase an entry today.
Wall Street analysts forecast NBTX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NBTX is 3.5 USD with a low forecast of 3.5 USD and a high forecast of 3.5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast NBTX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NBTX is 3.5 USD with a low forecast of 3.5 USD and a high forecast of 3.5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
0 Sell
Hold
Current: 21.030
Low
3.5
Averages
3.5
High
3.5
Current: 21.030
Low
3.5
Averages
3.5
High
3.5
TD Cowen
Buy
initiated
AI Analysis
2026-02-06
New
Reason
TD Cowen
Price Target
AI Analysis
2026-02-06
New
initiated
Buy
Reason
TD Cowen initiated coverage of Nanobiotix with a Buy rating and no price target. Nanobiotix's physics-based platform technologies have broad applicability free of biological constraints, the analyst tells investors in a research note. TD sees upside in the shares as the company expands into more tumor types.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
2025-11-04
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
2025-11-04
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Nanobiotix to EUR 23 from EUR 20 and keeps a Buy rating on the shares. The firm believes the company's "non-dilutive" financing arrangement with HealthCare Royalty brings validation.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NBTX
